Results 121 to 130 of about 48,159 (229)

Recalcitrant urticaria controlled with a combination of mycophenolate mofetil and sulfasalazine

International Journal of Women's Dermatology, 2021
Alyssa G. Ashbaugh, MD, Jenny E. Murase, MD   +1 more
doaj   +1 more source

Immune cells composition in the skin and subcutaneous adipose tissue of patients with systemic sclerosis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Systemic sclerosis (SSc) is a rare, chronic autoimmune disease characterized by fibrosis of the skin and/or internal organs. Emerging evidence suggests that subcutaneous adipose tissue may contribute to systemic inflammation and fibrosis in SSc.
Marija Geroldinger‐Simić, Ana E. Aguilar González, Gerald Exler, Georg Stary   +3 more
wiley   +1 more source

Adjuvant therapy of severe and/or refractory bullous pemphigoid with immunoadsorption – A prospective monocenter pilot study

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Bullous pemphigoid (BP) is the most common autoimmune blistering disease in the Western world. While remission is achieved in the majority of BP patients by long‐term use of corticosteroids with or without immunomodulants/immunosuppressants, national and international guidelines recommend adjuvant immunoadsorption (IA)
Maike M. Holtsche, Nina van Beek, Christoph M. Hammers, Artem Vorobyev, Michael Kasperkiewicz, Nina Schumacher, Philip Muck, Enno Schmidt   +7 more
wiley   +1 more source

Azathioprine or mycophenolate mofetil for pediatric autoimmune cytopenia: a propensity score-matched study. [PDF]

Blood Adv
Pincez T, Fernandes H, Leverger G, Barlogis V, Fahd M, Garnier N, Paillard C, Guitton C, Abou Chahla W, Pasquet M, Jeziorski E, Castelle M, Bayart S, Pellier I, Thomas C, Pagnier A, Benadiba J, Li Thiao Te V, Cheikh N, Lejeune J, Deparis M, Marie-Cardine A, Chastagner P, Desplantes C, Millot F, Vic P, Thouvenin S, Piguet C, Pluchart C, Leblanc T, Héritier S, Aladjidi N.   +31 more
europepmc   +1 more source

Current perspectives on KMT2A fusion proteins and menin inhibition in paediatric acute myeloid leukaemia

The FEBS Journal, EarlyView.
Genetic rearrangements resulting in the expression of KMT2A fusion alleles can lead to dramatic transcriptional disturbances that contribute to the onset of acute leukaemias. Fortunately, menin inhibition has emerged as a promising new class of targeted therapy.
Lydia Elaine Roets, Graeme Greenfield, Katrina Mairead Lappin   +2 more
wiley   +1 more source

The role of mycophenolate mofetil in the therapy of thyroid eye disease. [PDF]

Ther Adv Endocrinol Metab
Witowska A, Pawluczuk E, Szczepanek-Parulska E, Ruchala M.   +3 more
europepmc   +1 more source

Mucous Membrane Pemphigoid After Anti‐PD‐1 Therapy: Risk‐Stratified Management and Treatment Outcomes

International Journal of Dermatology, EarlyView.
ABSTRACT Mucous membrane pemphigoid (MMP) following anti‐programmed cell death‐1 (PD‐1) therapy is rare but increasingly reported. Management of high‐ and low‐risk MMP in this setting and the potential oncologic trade‐offs remain poorly defined. We performed a narrative synthesis of all published cases of anti‐PD‐1‐associated MMP, following MEDLINE ...
Serena Dienes, Negar Esfandiari, Steven Daveluy   +2 more
wiley   +1 more source

Effective Management of a Rare Case of Pediatric ANCA-Associated Vasculitis With Rituximab and Mycophenolate Mofetil. [PDF]

Am J Case Rep
Fang Y, Kurady A, Hashim FQ, Berger B, Rao A.   +4 more
europepmc   +1 more source

Successful Treatment of Pure Red Cell Aplasia in Systemic Lupus Erythematosus With a Combination of Rituximab and Mycophenolate Mofetil. [PDF]

Cureus
Carvalho MC, Fernandes Serodio J, Amaral MC, Oliveira S, Delgado Alves J.   +4 more
europepmc   +1 more source

Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Our findings show that greater proportions of litifilimab‐treated participants than placebo experienced 20%, 50%, 70% or 90% improvements in CLASI‐A score from baseline and CLASI‐A scores of 0–1 or 0–3. Similar results were observed using physician global assessments, supporting the Phase 2 LILAC study primary analysis in CLE.
Victoria P. Werth, Joseph F. Merola, Richard Furie, Kenneth Kalunian, Ronald F. van Vollenhoven, Juanita Romero‐Diaz, Qianyun Li, Weihong Yang, Catherine Barbey   +8 more
wiley   +1 more source